腹泻型肠易激综合征患者升结肠黏膜类胰蛋白酶、α1-抗胰蛋白酶的表达变化及其意义
|
摘要
目的:检测腹泻型肠易激综合征(IBS-D)患者和健康对照者升结肠黏膜类胰蛋白酶、α1-抗胰蛋白酶的表达水平,并探讨它们与IBS-D症状的关系。
方法:符合RomeⅢ标准的IBS-D患者20例、健康对照组10例纳入研究,在接受电子肠镜检查时取升结肠黏膜标本3块,称质量、生理盐水漂洗后迅速在2ml HBSS平衡盐液中37℃下孵育1 h,ELISA法和Western blotting法检测孵育上清液中类胰蛋白酶、α1-抗胰蛋白酶水平, RT-PCR法检测升结肠黏膜类胰蛋白酶、α1-抗胰蛋白酶mRAN表达。类胰蛋白酶、α1-抗胰蛋白酶表达水平与IBS-D患者的胃肠道症状评分进行相关性分析。
结果:
1、ELISA法结果:IBS-D患者升结肠黏膜组织孵育上清液中类胰蛋白酶浓度为(0.070±0.011)ug/g组织,健康对照组为(0.043±0.006) ug/g组织,差异有统计学意义(P=0.000);而α1-抗胰蛋白酶浓度为(2.36±1.05mg/g组织)与健康对照组为(2.68±1.19 mg/g组织)的差异无统计学意义(P=0.455)。类胰蛋白酶浓度与胃肠道症状评分(GSRS)呈正相关( r =0.592, P =0.008)。
2、RT-PCR法结果:IBS-D患者升结肠黏膜组织类胰蛋白酶相对表达度为0.83±0.06,健康对照组为0.58±0.13,差异有统计学意义( P =0.000);而α1-抗胰蛋白酶相对表达度为(1.02±0.19)与健康对照组为(0.97±0.17)的差异无统计学意义( P =0.413)。RT-PCR法检测的类胰蛋白酶相对表达度与GSRS也呈正相关(r=0.520, P =0.009)。
3、Western blotting法结果:IBS-D患者升结肠黏膜组织类胰蛋白酶相对浓度为0.53±0.09,健康对照组为0.23±0.08,差异有统计学意义(P=0.000);而α1-抗胰蛋白酶相对浓度为(0.81±0.15)与健康对照组为(0.80±0.11)的差异无统计学意义(P=0.761)。Western blotting法测定的类胰蛋白酶相对浓度与GSRS呈正相关( r =0.421,P=0.032)。
结论:腹泻型肠易激综合征患者升结肠黏膜中类胰蛋白酶的表达水平增加,而α1-抗胰蛋白酶表达无明显差异,这种变化与IBS-D的消化道症状相关,因此,升结肠肥大细胞中类胰蛋白酶表达增加可能与IBS-D症状的发生机制有关。
Aim: To detect the contents of tryptase andα1-antitrypsin in the ascending colonic mucosa in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore their role in the pathogenesis of this disorder.
Methods: Twenty patients with IBS-D fulfilling the Rome III criteria and ten healthy volunteers were included in this study. Three biopsy samples were collected from the ascending colon during the colonoscopy, and then incubated in 2ml HBSS 37℃for 1h. The concentrations of tryptase andα1-antitrypsin in the supernatants were detected by enzyme-linked immunosorbent assay (ELISA). The proteins and mRNA of tryptase andα1-antitrypsin in the mucosa were detected by Western blotting and RT-PCR respectively.The relationship between gastrointestinal symptom rating scale (GSRS) and the contents of tryptase in the ascending colon were also analyzed.
Results: The contents of tryptase in ascending colon mucosa supernatants of the IBS-D patients detected by ELISA were (0.070±0.011)ug/g tissue,while in the healthy volunteers were (0.043±0.006) ug/g tissue. There was a significant difference between them( P =0.000). Hower, the mean content ofα1-antitrypsin in the supernatants of the IBS-D patients (2.36±1.05)mg/g tissue detected by ELISA was not different from that in the healthy volunteers (2.68±1.19)mg/g tissue ( P=0.455). The contents of tryptase were positively correlated with GSRS score( r = 0.592, P = 0.008).
The relative expression of tryptase mRNA in the ascending colon mucosa of the IBS-D patients detected by RT-PCR was 0.83±0.06,while in the healthy volunteers was 0.23±0.08. The difference has a statistical significance( P =0.000). The relative expression ofα1-antitrypsin mRNA in the ascending colon mucosa of the IBS-D patients detected by RT-PCR was 1.02±0.19,while in the healthy volunteers was 0.97±0.17. There was not a significant difference between them( P =0.413). The relative expression of mRNA of tryptase was positively correlated with GSRS score also( r = 0.520, P = 0.009).
The relative expression of tryptase in the ascending colon mucosa of the IBS-D patients detected by Western blotting was 0.53±0.09,while in the healthy volunteers was 0.23±0.08. The difference of the results has statistical sense( P =0.000). The relative expression ofα1-antitrypsin in ascending colon mucosa of the IBS-D patients detected by Western blotting was 0.81±0.15,while in the healthy volunteers was 0.80±0.11. The difference of the results has no statistical sense( P =0.761). The relative expression of tryptase was positively correlated with GSRS score( r = 0.421, P = 0.032).
Conclusion: The expression of tryptase in the ascending colon of IBS-D patients increased, but ofα1-antitrypsin not, and this change is related to gastrointestinal symptoms. Therefore, excessive expression of tryptase in the colon may be involved in the pathogenesis of IBS-D.
方法:符合RomeⅢ标准的IBS-D患者20例、健康对照组10例纳入研究,在接受电子肠镜检查时取升结肠黏膜标本3块,称质量、生理盐水漂洗后迅速在2ml HBSS平衡盐液中37℃下孵育1 h,ELISA法和Western blotting法检测孵育上清液中类胰蛋白酶、α1-抗胰蛋白酶水平, RT-PCR法检测升结肠黏膜类胰蛋白酶、α1-抗胰蛋白酶mRAN表达。类胰蛋白酶、α1-抗胰蛋白酶表达水平与IBS-D患者的胃肠道症状评分进行相关性分析。
结果:
1、ELISA法结果:IBS-D患者升结肠黏膜组织孵育上清液中类胰蛋白酶浓度为(0.070±0.011)ug/g组织,健康对照组为(0.043±0.006) ug/g组织,差异有统计学意义(P=0.000);而α1-抗胰蛋白酶浓度为(2.36±1.05mg/g组织)与健康对照组为(2.68±1.19 mg/g组织)的差异无统计学意义(P=0.455)。类胰蛋白酶浓度与胃肠道症状评分(GSRS)呈正相关( r =0.592, P =0.008)。
2、RT-PCR法结果:IBS-D患者升结肠黏膜组织类胰蛋白酶相对表达度为0.83±0.06,健康对照组为0.58±0.13,差异有统计学意义( P =0.000);而α1-抗胰蛋白酶相对表达度为(1.02±0.19)与健康对照组为(0.97±0.17)的差异无统计学意义( P =0.413)。RT-PCR法检测的类胰蛋白酶相对表达度与GSRS也呈正相关(r=0.520, P =0.009)。
3、Western blotting法结果:IBS-D患者升结肠黏膜组织类胰蛋白酶相对浓度为0.53±0.09,健康对照组为0.23±0.08,差异有统计学意义(P=0.000);而α1-抗胰蛋白酶相对浓度为(0.81±0.15)与健康对照组为(0.80±0.11)的差异无统计学意义(P=0.761)。Western blotting法测定的类胰蛋白酶相对浓度与GSRS呈正相关( r =0.421,P=0.032)。
结论:腹泻型肠易激综合征患者升结肠黏膜中类胰蛋白酶的表达水平增加,而α1-抗胰蛋白酶表达无明显差异,这种变化与IBS-D的消化道症状相关,因此,升结肠肥大细胞中类胰蛋白酶表达增加可能与IBS-D症状的发生机制有关。
Aim: To detect the contents of tryptase andα1-antitrypsin in the ascending colonic mucosa in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore their role in the pathogenesis of this disorder.
Methods: Twenty patients with IBS-D fulfilling the Rome III criteria and ten healthy volunteers were included in this study. Three biopsy samples were collected from the ascending colon during the colonoscopy, and then incubated in 2ml HBSS 37℃for 1h. The concentrations of tryptase andα1-antitrypsin in the supernatants were detected by enzyme-linked immunosorbent assay (ELISA). The proteins and mRNA of tryptase andα1-antitrypsin in the mucosa were detected by Western blotting and RT-PCR respectively.The relationship between gastrointestinal symptom rating scale (GSRS) and the contents of tryptase in the ascending colon were also analyzed.
Results: The contents of tryptase in ascending colon mucosa supernatants of the IBS-D patients detected by ELISA were (0.070±0.011)ug/g tissue,while in the healthy volunteers were (0.043±0.006) ug/g tissue. There was a significant difference between them( P =0.000). Hower, the mean content ofα1-antitrypsin in the supernatants of the IBS-D patients (2.36±1.05)mg/g tissue detected by ELISA was not different from that in the healthy volunteers (2.68±1.19)mg/g tissue ( P=0.455). The contents of tryptase were positively correlated with GSRS score( r = 0.592, P = 0.008).
The relative expression of tryptase mRNA in the ascending colon mucosa of the IBS-D patients detected by RT-PCR was 0.83±0.06,while in the healthy volunteers was 0.23±0.08. The difference has a statistical significance( P =0.000). The relative expression ofα1-antitrypsin mRNA in the ascending colon mucosa of the IBS-D patients detected by RT-PCR was 1.02±0.19,while in the healthy volunteers was 0.97±0.17. There was not a significant difference between them( P =0.413). The relative expression of mRNA of tryptase was positively correlated with GSRS score also( r = 0.520, P = 0.009).
The relative expression of tryptase in the ascending colon mucosa of the IBS-D patients detected by Western blotting was 0.53±0.09,while in the healthy volunteers was 0.23±0.08. The difference of the results has statistical sense( P =0.000). The relative expression ofα1-antitrypsin in ascending colon mucosa of the IBS-D patients detected by Western blotting was 0.81±0.15,while in the healthy volunteers was 0.80±0.11. The difference of the results has no statistical sense( P =0.761). The relative expression of tryptase was positively correlated with GSRS score( r = 0.421, P = 0.032).
Conclusion: The expression of tryptase in the ascending colon of IBS-D patients increased, but ofα1-antitrypsin not, and this change is related to gastrointestinal symptoms. Therefore, excessive expression of tryptase in the colon may be involved in the pathogenesis of IBS-D.
引文
[1]Mostafa R. Rome III:The functional gastrointestinal disorders,third edition,2006[J]. World J Gastroenterol, 2008, 14(13): 2124-2125.
[2]Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to RomeⅡcriteria :an Australian population-based study[J]. InternMed J, 2006, 36(1): 28-36.
[3]马红英,谌颖琦,刘玉成,樊龙忠,隋杰,张明华,蒋国顺.湛江市肠易激综合征危险因素的病例对照研究[J].中华流行病学杂志, 2001, 22(6): 452-454.
[4]Whitehead WE, Bumett CK, CooK EW. Impact of irritable bowel syndrome on quality of life[J]. Dig Dis Sci, 1996, 41(11): 2248-2253.
[5]王承党,郑雪雁,郑玮玮.结肠黏膜低度炎症对大鼠内脏感觉的影响[J].世界华人消化杂志, 2009, 17(16): 1621-1625.
[6]王承党.重视黏膜炎症在肠易激综合征发病机制中的地位[J].胃肠病学, 2008, 13(9): 513-515.
[7]Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome[J]. Gut, 1973, 14(2): 125-132 .
[8]王承党,郭朝书.肥大细胞和类胰蛋白酶在腹泻型肠易激综合征升结肠黏膜中的表达及意义[J].世界华人消化杂志, 2010, 18(16): 1682-1686.
[9]Longs t reth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders[J]. Gastroenterology, 2006, 130(5): 1480-1491.
[10]Dinan TG, O'Keane V, O'Boyle C, Chua A, Keeling PW. A comparison of the mental status, personality profiles and life events of patients with irritablebowel syndrome and peptic ulcer disease[J]. Acta Psychiatr Scand, 1991, 84(1): 26-28.
[11]Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M,Barbara G,Beck P,Bunnett NW,Sharkey KA,Ferraz JG,Shaffer E,Vergnolle N.Role for protease activity in visceral pain in irritable bowel syndrome[J]. J ClinInvest,2007, 117(3): 636-647.
[12]Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the Mucosal immune system in irritable bowel symdrome[J]. Gastroenterology, 2002, 122(7): 1778-1783
[13]Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypesin irritable bowel syndrome: evidence for an inflammatory component[J]? Gut, 2003, 52(1): 91-93.
[14]鞠辉,张小芳,刘希双,魏良洲.感染后与非感染后肠易激综合征患者结肠黏膜SP与IL-2、IFN-γ表达的相关性[J].世界华人消化杂志, 2006, 14(32): 3116-3120.
[15]Smout A, Azpiroz F, Coremans G, Dapoigny M, Collins S, Müller-Lissner S, Pace F, StockbrüggerR, Vatn M, Whorwell P. Potential pitfalls in the differential diagnosis of irritable bowel syndrome[J]. Digestion, 2000, 61(4): 247-256.
[16]Barbara G, Corinaldesi R. Probiotics: could they turn out to be ineffective in irritable bowel syndrome[J]? Dig Liver Dis, 2000, 32(4): 302-304.
[17]Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease[J]? Gastroenterol Clin North Am , 2005, 34(2): 235-245, vi-vii.
[18]Spiller RC. Inflammation as a basis for functional GI disorders[J]. Best Pract Res Clin, Gastroenterol, 2004, 18(4): 641-661.
[19]Franceschini B, Ceva-Grimaldi G, Russo C. The complex functions of mast cells in chronic human liver diseases[J]. Digestive Diseases & Sciences, 2006, 51(12): 2248-2256.
[20]Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system[J]. Immunobiology, 2008, 213(3): 251-260.
[21]Ito A, Hagiyama M. Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1[J]. Smooth Muscle Res, 2008, 44(2): 83-93.
[22]呼格吉乐图,苏布达,王志,杜山,赵治国,李云章,许乐仁.肥大细胞的组织化学与超微结构异质性[J].细胞生物学杂志, 2007, 29(6): 840-844.
[23]Barbara G, Wang BX, Giorgi VS, Cremon C, DiNardo G, Trevisani M, Campi B, Geppetti P,Tonini M, Nigel W.B, Grundy D, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome[J]. Gastroenterology, 2004, 126(3): 693–702.
[24] Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Blaszyk H, Crowellr MD., Sharkey KA., Gershon MD., Mawe GM., Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome[J]. Gastroenterology, 2004, 126(7): 1657-1664.
[25]Zou BC, Dong L, Wang Y, WANG SH, CAO MB. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome[J]. Chin Med J(Engl), 2007, 120(23): 2069-2074.
[26]Wang GD, Wang XY, Hu HZ, Fang XC, Liu S, Gao N, Xia Y, Wood JD. Angiotensin receptors and actions in guinea pig enteric nervous system[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 289(9): G614-G626.
[27]Delafoy L, Raymond F, Doherty AM, EschalierA, Diop L. Role of nerve growth factor in thetrinitrobenzene sulfonic acid-induced colonic hypersensitivity[J]. Pain, 2003, 105(3): 489-497.
[28]Barreau F, Cartier C, Ferrier L, Fioramonti J, Bueno L. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats[J]. Gastroenteroloyg, 2004, 127(2): 524-534.
[29]Papadakis KA, Targan SR, Tumor necrosis factor:biology and therapeutic inhibitors[J]. Gastroenterology, 2000, 119(4): 1148-1157.
[30]Barbara G, De Giorgio R, Stanghellini V, C.Cremon, B.Salvioli, R.Corinaldesi. New pathophysiological mechanisms in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2004, 20 Suppl 2: 1-9.
[31]Mican JA, Arora N, Burd PR, Metcalfe DD. Passive cutaneous anaphylaxis in mouse skin is associated with local accumulation of interleukin-6 mRNA and immunoreactive interleukin-6 protein[J]. J Allergy Clin Immunol, 1992, 90(5): 815–824.
[32]Kim SH, Shin TY. Amomum xanthiodes inhibits mast cell–mediated allergic reactions through the inhibition of histamine release and inflammatory cytokine production[J]. Exp Biol Med, 2005, 230(9): 681–687.
[33]Million M, Grigoriadis DE, Sullivan S, Crowe PD, McRoberts JA, Zhou H, Saunders PR, Maillot C, Mayer EA, TachéY. A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts Stressinduced visceral hyperalgesia and colonic motorfunction in rats[J]. Brain Res, 2003, 985(1): 32-42.
[34]陆超,殷莲华,金惠铭.类胰蛋白酶与疾病[J].中国病理生理杂志, 2002, 18(6): 687-689.
[35]He S, Walls AF. Human mast cell tryptase:a stimulus of microvascular leakage and mast cell activation[J]. Eur J Pharmacol, 1997, 328(1): 89.
[36]Lidington EA, Steinberg R, Kinderlerer AR, Landis RC, Ohba M, Samarel A, Haskard DO,Mason JC.A role for proteinase-activated receptor 2 and PKC-κin thrombin-mediated induction of decay-accelerating factor on human endothelial cells[J]. Am J Physiol Cell Physiol, 2005, 289(6): C1437 -1447.
[37]DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/ 2[J]. J Cell Biol, 2000, 148(6): 1267-1281.
[38]Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A,Izbéki F, Fioramonti J, Wittmann T, Bueno L. Increased faecal serine protease activity indiarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and Sensitivity[J]. Gut, 2008, 57(5): 591-599.
[39]Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome[J]. J Clin Invest, 2007, 117(3): 636-647.
[40]Kayssi A, Amadesi S, Bautista F, Bunnett NW, Vanner S. Mechanisms of protease-activated receptor 2 evoked hyperexcitability of nociceptive neurons innervating the mouse colon[J]. J Physiol, 2007, 580(3): 977-991.
[41]Vergnolle. Clinical relevance of proteinase activated receptors in the gut[J]. Gut, 2005, 54(6): 867-874.
[42]Reed D.E., Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, Bunnett NW, Vanner SJ. Mast cell tryptase and proteinase- activated receptor 2 induce hyperexcitability of guinea pig submucosal neurons[J]. J Physiol, 2003, 547(2): 531-542.
[43]Reh G, Nerli B, Pieo G. Isolation of alpha-1-antitrypsin from human plasma by partitioning in aqueous biphasie systems of polyethyleneglycol-phosphate[J]. J Chromatography B, 2002, 780(2): 389-396.
[44]Crowther DC, Belorgey D, Miranda E. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies[J]. Eur J Hum Genet, 2004, 12(3): 167-172.
[45]Shaker SB, Maltbaek N, Brand P. Quantitative computed tomography and aerosol morphometry in COPD and alphal-antitrypsin deficiency[J]. Eur Respir J, 2005, 25(1): 23-30.
[46]Crowell MD, Jones MP, Harris LA, Dineen TN, Schettler VA, Dlden KW. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes[J]. Curr Opin Investig Drugs, 2004, 5(7): 736-742.
[47]赵战芝,杨永宗,王佐,危当恒,史文元. LDTI抑制肥大细胞类胰蛋白酶活性并阻断其抑制胆固醇流出能力的研究[J].国际病理科学与临床杂志, 2005, 25(6):471-476.
[48]Hallgren J, Pejler G. Biology of mast cell tryptase-An inflammatory mediator[J]. FEBS J, 2006, 273(9): 1871～1895.
[49]J.K.Brown, C.A.Jones, L.A.Rooney, G.H.Caughey. Mast cell tryptase actibates extracell-ular-regulated kinases(p44/p42)in airway smooth-muscle cells:importance of proteolytic eyents,timecourse,and role in mediating mitogensis[J]. Am J Respir Cell Mol Biol, 2001, 107(6): 1039-1045.
[50]谢华,何韶衡.亮肽素、TLCK和乳铁蛋白对人结肠肥大细胞类胰蛋白酶释放的影响[J].中国病理生理杂志, 2005, 21(7): 1411-1414.
[51]谢华,何韶衡.鱼精蛋白对人结肠肥大细胞IgE依赖性与非依赖性类胰蛋白酶释放的调节[J].汕头大学医学院学报, 2004, 17(1): 1-4.
[1]Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to RomeⅡcriteria: an Australian population-based study[J]. Intern Med J, 2006, 36(1): 28-36.
[2]马红英,谌颖琦,刘玉成,樊龙忠,隋杰,张明华,蒋国顺.湛江市肠易激综合征危险因素的病例对照研究[J].中华流行病学杂志, 2001, 22(6): 452-454.
[3]Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system[J]. Immunobiology, 2008, 213(3-4): 251-260.
[4]Park JH, Rhee PL, Kim HS. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome[J]. Gastroenterol Hepatol, 2006, 21(1 pt1): 71-78.
[5]王承党,郭朝书.肥大细胞和类胰蛋白酶在腹泻型肠易激综合征升结肠黏膜中的表达及意义[J].世界华人消化杂志, 2010, 18(16): 1682-1686.
[6]Lidington EA, Steinberg R, Kinderlerer AR, Landis RC, Ohba M, Samarel A, Haskard DO, Mason JC. A role for proteinase-activated receptor 2 and PKC-κin thrombin-mediated induction of decay-accelerating factor on human endothelial cells[J]. Am J Physiol Cell Physiol,2005, 289(6): C1437–C1447.
[7]DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2[J]. J Cell Biol, 2000, 148(6): 1267-1281.
[8]Gecse K, Róka R, Ferrier L, M Leveque1, H Eutamene1, Cartier1, A Ait-Belgnaoui1, A Rosztóczy2, F Izbéki2, J Fioramonti1, T Wittmann2, L Bueno.Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and Sensitivity[J]. Gut, 2008 , 57(5): 591-599.
[9]Kayssi A, Amadesi S, Bautista F, Bunnett NW, Vanner S. Mechanisms of protease-activated receptor 2 evoked hyperexcitability of nociceptive neurons innervating the mouse colon[J]. J Physiol, 2007, 580(pt.3): 977-991.
[10]Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N.Role for protease activity in visceral pain in irritable bowel syndrome[J]. Clin Invest, 2007, 117(3): 636-647.
[11]Puri N, Roche PA. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms[J]. Proceedings of the National Academy of Sciences(USA), 2008, 105(7): 2580-2585.
[12]董文珠,李兆申,邹多武,许国铭,邹晓平,朱爱勇,尹宁.肠易激综合征患者肠黏膜肥大细胞与P物质的相关性[J].中华内科杂志, 2003, 42(9): 611-614.
[13]Zou BC, Dong L, Wang Y, Wang SH, Cao MB. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome[J]. Chin Med J (Engl), 2007, 120(23): 2069-2074.
[14]Wang GD, Wang XY, Hu HZ, Fang XC, Liu S, Gao N, Xia Y, Wood JD..Angiotensin receptors and actions in guinea pig enteric nervous system[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 289(3): G614-G626.
[15]Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17:an effector CD4 T cell lineage with regulatory T cell ties[J]. Immunity, 2006, 24(6): 677-688.
[16]Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryp tamine signalling in patients with constipation and diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology, 2006, 130(1): 34-43.
[17]Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome[J]. Am J Gastroenterol, 2001, 96(9):2671-2676.
[18]Grider JR, Piland BE. The peristaltic reflex induced by short-chain fatty acids is mediated by sequential release of 5-HT and neuronal CGRP but not BDNF[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 292(1): G429-437.
[19]Muller-Lissner SA, Fumagalli I, Bardhan KD, Bardhan3, F. Pace4,E. Pecher5, B. Nault5, P. Rüegg. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain , bloating and constipation[J]. Aliment Pharmacol Ther, 2001, 15(10): 1655–1666.
[20]Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R.Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome[J]. Gastroenterology, 2004, 126(3): 693–702.
[21]Sun Q, Li W, She R, Wang D, Han D, Li R, Ding Y, Yue Z. Evidence for a role of mast cells in the mucosal injury induced by Newcastle disease virus[J]. Poult Sci, 2009, 88(3): 554–561.
[22]Francis H, Glaser S, DeMorrow S, Gaudio E, Ueno Y, Venter J, Dostal D, Onori P, Franchitto A, Marzioni M, Vaculin S, Vaculin B, Katki K, Stutes M, Savage J, Alpini G. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway[J]. Am J Physiol Cell Physiol, 2008, 295(2): C499-C513.
[23]Schneider E, M Rolli-Derkinderen, M Arock, Michel Dy. Trends in histamine research: New functions during immune responses and hematopoiesis[J]. Trends Immunol, 2002, 23(5): 255–262.
[24]Liu S, Xia Y, Hu H, Ren J, Gao C, Wood JD. Histamine H3 receptor-mediated suppression of inhibitory synaptic transmission in the submucous plexus of guinea-pig small intestine[J]. Eur J Pharmacol, 2000, 397(1): 49-54.
[25]Eutamene H, Theodorou V, Fioramonti J. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats[J]. Physiol, 2003, 553(pt.3): 959-966.
[26]Crowell MD, Jones MP, Harris LA, Dineen TN, Schettler VA, Olden KW. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes[J]. Curr Opin Investig Drugs, 2004, 5(7): 736-742.
[27]王承党,郑雪雁,郑玮玮.结肠黏膜低度炎症对大鼠内脏感觉的影响[J].世界华人消化杂志, 2009, 17(16): 1621-1625.
[28]王承党.重视黏膜炎症在肠易激综合征发病机制中的地位[J].胃肠病学, 2008 , 13(9): 513-515.
[29]Rijnierse A, Koster AS, Frans P N, Kraneveld AD. TNF-αis crucial for the development of mast cell-dependent colitis in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 291(5): G969-G976.
[30]Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors[J]. Gastroenterology, 2000, 119(4): 1148-1157.
[31] Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome[J]. Cut, 2001, 49(6): 743-745.
[32]Kim SH, Shin TY. Amomum xanthiodes inhibits mast cell- mediated allergic reactions through the inhibition of histamine release and inflammatory cytokine production[J]. Exp Biol Med, 2005, 230(9): 681–687.
[33]Msxwell PR, Rink E, Kumar D. Antibiotics increase functional abdominal symptoms[J]. Gastroenterology, 2002, 97(1): 104-108.
[34]Farthing MJG. Irritable bowel , irritable body , or irritable brain[J]? Br Med J, 1995, 310(6973): 171-175.
[35]Nicholl CG, Friedman G, Whitehead WE, Bloom SR. Effect of enprostil on gastric emptying , intestinal transit time and post-prandial release of gastrointestinal peptides[J]. Digestion, 1989, 43(1-2): 47-54.
[36]Gwee KA, Collins SM, Read NW. Increased rectal mucosal expression of interleukin 1βin recently acquired post-infectious irritable bowel syndrome[J]. Gut, 2003, 52(4): 523-526.
[37]Gonsalkorale WM, Perrey C, Pravica V, P J Whorwell, I V Hutchinson. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component[J]. Gut, 2003, 52(1): 91-93.
[2]Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to RomeⅡcriteria :an Australian population-based study[J]. InternMed J, 2006, 36(1): 28-36.
[3]马红英,谌颖琦,刘玉成,樊龙忠,隋杰,张明华,蒋国顺.湛江市肠易激综合征危险因素的病例对照研究[J].中华流行病学杂志, 2001, 22(6): 452-454.
[4]Whitehead WE, Bumett CK, CooK EW. Impact of irritable bowel syndrome on quality of life[J]. Dig Dis Sci, 1996, 41(11): 2248-2253.
[5]王承党,郑雪雁,郑玮玮.结肠黏膜低度炎症对大鼠内脏感觉的影响[J].世界华人消化杂志, 2009, 17(16): 1621-1625.
[6]王承党.重视黏膜炎症在肠易激综合征发病机制中的地位[J].胃肠病学, 2008, 13(9): 513-515.
[7]Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome[J]. Gut, 1973, 14(2): 125-132 .
[8]王承党,郭朝书.肥大细胞和类胰蛋白酶在腹泻型肠易激综合征升结肠黏膜中的表达及意义[J].世界华人消化杂志, 2010, 18(16): 1682-1686.
[9]Longs t reth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders[J]. Gastroenterology, 2006, 130(5): 1480-1491.
[10]Dinan TG, O'Keane V, O'Boyle C, Chua A, Keeling PW. A comparison of the mental status, personality profiles and life events of patients with irritablebowel syndrome and peptic ulcer disease[J]. Acta Psychiatr Scand, 1991, 84(1): 26-28.
[11]Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M,Barbara G,Beck P,Bunnett NW,Sharkey KA,Ferraz JG,Shaffer E,Vergnolle N.Role for protease activity in visceral pain in irritable bowel syndrome[J]. J ClinInvest,2007, 117(3): 636-647.
[12]Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the Mucosal immune system in irritable bowel symdrome[J]. Gastroenterology, 2002, 122(7): 1778-1783
[13]Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypesin irritable bowel syndrome: evidence for an inflammatory component[J]? Gut, 2003, 52(1): 91-93.
[14]鞠辉,张小芳,刘希双,魏良洲.感染后与非感染后肠易激综合征患者结肠黏膜SP与IL-2、IFN-γ表达的相关性[J].世界华人消化杂志, 2006, 14(32): 3116-3120.
[15]Smout A, Azpiroz F, Coremans G, Dapoigny M, Collins S, Müller-Lissner S, Pace F, StockbrüggerR, Vatn M, Whorwell P. Potential pitfalls in the differential diagnosis of irritable bowel syndrome[J]. Digestion, 2000, 61(4): 247-256.
[16]Barbara G, Corinaldesi R. Probiotics: could they turn out to be ineffective in irritable bowel syndrome[J]? Dig Liver Dis, 2000, 32(4): 302-304.
[17]Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease[J]? Gastroenterol Clin North Am , 2005, 34(2): 235-245, vi-vii.
[18]Spiller RC. Inflammation as a basis for functional GI disorders[J]. Best Pract Res Clin, Gastroenterol, 2004, 18(4): 641-661.
[19]Franceschini B, Ceva-Grimaldi G, Russo C. The complex functions of mast cells in chronic human liver diseases[J]. Digestive Diseases & Sciences, 2006, 51(12): 2248-2256.
[20]Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system[J]. Immunobiology, 2008, 213(3): 251-260.
[21]Ito A, Hagiyama M. Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1[J]. Smooth Muscle Res, 2008, 44(2): 83-93.
[22]呼格吉乐图,苏布达,王志,杜山,赵治国,李云章,许乐仁.肥大细胞的组织化学与超微结构异质性[J].细胞生物学杂志, 2007, 29(6): 840-844.
[23]Barbara G, Wang BX, Giorgi VS, Cremon C, DiNardo G, Trevisani M, Campi B, Geppetti P,Tonini M, Nigel W.B, Grundy D, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome[J]. Gastroenterology, 2004, 126(3): 693–702.
[24] Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Blaszyk H, Crowellr MD., Sharkey KA., Gershon MD., Mawe GM., Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome[J]. Gastroenterology, 2004, 126(7): 1657-1664.
[25]Zou BC, Dong L, Wang Y, WANG SH, CAO MB. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome[J]. Chin Med J(Engl), 2007, 120(23): 2069-2074.
[26]Wang GD, Wang XY, Hu HZ, Fang XC, Liu S, Gao N, Xia Y, Wood JD. Angiotensin receptors and actions in guinea pig enteric nervous system[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 289(9): G614-G626.
[27]Delafoy L, Raymond F, Doherty AM, EschalierA, Diop L. Role of nerve growth factor in thetrinitrobenzene sulfonic acid-induced colonic hypersensitivity[J]. Pain, 2003, 105(3): 489-497.
[28]Barreau F, Cartier C, Ferrier L, Fioramonti J, Bueno L. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats[J]. Gastroenteroloyg, 2004, 127(2): 524-534.
[29]Papadakis KA, Targan SR, Tumor necrosis factor:biology and therapeutic inhibitors[J]. Gastroenterology, 2000, 119(4): 1148-1157.
[30]Barbara G, De Giorgio R, Stanghellini V, C.Cremon, B.Salvioli, R.Corinaldesi. New pathophysiological mechanisms in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2004, 20 Suppl 2: 1-9.
[31]Mican JA, Arora N, Burd PR, Metcalfe DD. Passive cutaneous anaphylaxis in mouse skin is associated with local accumulation of interleukin-6 mRNA and immunoreactive interleukin-6 protein[J]. J Allergy Clin Immunol, 1992, 90(5): 815–824.
[32]Kim SH, Shin TY. Amomum xanthiodes inhibits mast cell–mediated allergic reactions through the inhibition of histamine release and inflammatory cytokine production[J]. Exp Biol Med, 2005, 230(9): 681–687.
[33]Million M, Grigoriadis DE, Sullivan S, Crowe PD, McRoberts JA, Zhou H, Saunders PR, Maillot C, Mayer EA, TachéY. A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts Stressinduced visceral hyperalgesia and colonic motorfunction in rats[J]. Brain Res, 2003, 985(1): 32-42.
[34]陆超,殷莲华,金惠铭.类胰蛋白酶与疾病[J].中国病理生理杂志, 2002, 18(6): 687-689.
[35]He S, Walls AF. Human mast cell tryptase:a stimulus of microvascular leakage and mast cell activation[J]. Eur J Pharmacol, 1997, 328(1): 89.
[36]Lidington EA, Steinberg R, Kinderlerer AR, Landis RC, Ohba M, Samarel A, Haskard DO,Mason JC.A role for proteinase-activated receptor 2 and PKC-κin thrombin-mediated induction of decay-accelerating factor on human endothelial cells[J]. Am J Physiol Cell Physiol, 2005, 289(6): C1437 -1447.
[37]DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/ 2[J]. J Cell Biol, 2000, 148(6): 1267-1281.
[38]Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A,Izbéki F, Fioramonti J, Wittmann T, Bueno L. Increased faecal serine protease activity indiarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and Sensitivity[J]. Gut, 2008, 57(5): 591-599.
[39]Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome[J]. J Clin Invest, 2007, 117(3): 636-647.
[40]Kayssi A, Amadesi S, Bautista F, Bunnett NW, Vanner S. Mechanisms of protease-activated receptor 2 evoked hyperexcitability of nociceptive neurons innervating the mouse colon[J]. J Physiol, 2007, 580(3): 977-991.
[41]Vergnolle. Clinical relevance of proteinase activated receptors in the gut[J]. Gut, 2005, 54(6): 867-874.
[42]Reed D.E., Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, Bunnett NW, Vanner SJ. Mast cell tryptase and proteinase- activated receptor 2 induce hyperexcitability of guinea pig submucosal neurons[J]. J Physiol, 2003, 547(2): 531-542.
[43]Reh G, Nerli B, Pieo G. Isolation of alpha-1-antitrypsin from human plasma by partitioning in aqueous biphasie systems of polyethyleneglycol-phosphate[J]. J Chromatography B, 2002, 780(2): 389-396.
[44]Crowther DC, Belorgey D, Miranda E. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies[J]. Eur J Hum Genet, 2004, 12(3): 167-172.
[45]Shaker SB, Maltbaek N, Brand P. Quantitative computed tomography and aerosol morphometry in COPD and alphal-antitrypsin deficiency[J]. Eur Respir J, 2005, 25(1): 23-30.
[46]Crowell MD, Jones MP, Harris LA, Dineen TN, Schettler VA, Dlden KW. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes[J]. Curr Opin Investig Drugs, 2004, 5(7): 736-742.
[47]赵战芝,杨永宗,王佐,危当恒,史文元. LDTI抑制肥大细胞类胰蛋白酶活性并阻断其抑制胆固醇流出能力的研究[J].国际病理科学与临床杂志, 2005, 25(6):471-476.
[48]Hallgren J, Pejler G. Biology of mast cell tryptase-An inflammatory mediator[J]. FEBS J, 2006, 273(9): 1871～1895.
[49]J.K.Brown, C.A.Jones, L.A.Rooney, G.H.Caughey. Mast cell tryptase actibates extracell-ular-regulated kinases(p44/p42)in airway smooth-muscle cells:importance of proteolytic eyents,timecourse,and role in mediating mitogensis[J]. Am J Respir Cell Mol Biol, 2001, 107(6): 1039-1045.
[50]谢华,何韶衡.亮肽素、TLCK和乳铁蛋白对人结肠肥大细胞类胰蛋白酶释放的影响[J].中国病理生理杂志, 2005, 21(7): 1411-1414.
[51]谢华,何韶衡.鱼精蛋白对人结肠肥大细胞IgE依赖性与非依赖性类胰蛋白酶释放的调节[J].汕头大学医学院学报, 2004, 17(1): 1-4.
[1]Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to RomeⅡcriteria: an Australian population-based study[J]. Intern Med J, 2006, 36(1): 28-36.
[2]马红英,谌颖琦,刘玉成,樊龙忠,隋杰,张明华,蒋国顺.湛江市肠易激综合征危险因素的病例对照研究[J].中华流行病学杂志, 2001, 22(6): 452-454.
[3]Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system[J]. Immunobiology, 2008, 213(3-4): 251-260.
[4]Park JH, Rhee PL, Kim HS. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome[J]. Gastroenterol Hepatol, 2006, 21(1 pt1): 71-78.
[5]王承党,郭朝书.肥大细胞和类胰蛋白酶在腹泻型肠易激综合征升结肠黏膜中的表达及意义[J].世界华人消化杂志, 2010, 18(16): 1682-1686.
[6]Lidington EA, Steinberg R, Kinderlerer AR, Landis RC, Ohba M, Samarel A, Haskard DO, Mason JC. A role for proteinase-activated receptor 2 and PKC-κin thrombin-mediated induction of decay-accelerating factor on human endothelial cells[J]. Am J Physiol Cell Physiol,2005, 289(6): C1437–C1447.
[7]DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2[J]. J Cell Biol, 2000, 148(6): 1267-1281.
[8]Gecse K, Róka R, Ferrier L, M Leveque1, H Eutamene1, Cartier1, A Ait-Belgnaoui1, A Rosztóczy2, F Izbéki2, J Fioramonti1, T Wittmann2, L Bueno.Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and Sensitivity[J]. Gut, 2008 , 57(5): 591-599.
[9]Kayssi A, Amadesi S, Bautista F, Bunnett NW, Vanner S. Mechanisms of protease-activated receptor 2 evoked hyperexcitability of nociceptive neurons innervating the mouse colon[J]. J Physiol, 2007, 580(pt.3): 977-991.
[10]Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N.Role for protease activity in visceral pain in irritable bowel syndrome[J]. Clin Invest, 2007, 117(3): 636-647.
[11]Puri N, Roche PA. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms[J]. Proceedings of the National Academy of Sciences(USA), 2008, 105(7): 2580-2585.
[12]董文珠,李兆申,邹多武,许国铭,邹晓平,朱爱勇,尹宁.肠易激综合征患者肠黏膜肥大细胞与P物质的相关性[J].中华内科杂志, 2003, 42(9): 611-614.
[13]Zou BC, Dong L, Wang Y, Wang SH, Cao MB. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome[J]. Chin Med J (Engl), 2007, 120(23): 2069-2074.
[14]Wang GD, Wang XY, Hu HZ, Fang XC, Liu S, Gao N, Xia Y, Wood JD..Angiotensin receptors and actions in guinea pig enteric nervous system[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 289(3): G614-G626.
[15]Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17:an effector CD4 T cell lineage with regulatory T cell ties[J]. Immunity, 2006, 24(6): 677-688.
[16]Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryp tamine signalling in patients with constipation and diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology, 2006, 130(1): 34-43.
[17]Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome[J]. Am J Gastroenterol, 2001, 96(9):2671-2676.
[18]Grider JR, Piland BE. The peristaltic reflex induced by short-chain fatty acids is mediated by sequential release of 5-HT and neuronal CGRP but not BDNF[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 292(1): G429-437.
[19]Muller-Lissner SA, Fumagalli I, Bardhan KD, Bardhan3, F. Pace4,E. Pecher5, B. Nault5, P. Rüegg. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain , bloating and constipation[J]. Aliment Pharmacol Ther, 2001, 15(10): 1655–1666.
[20]Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R.Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome[J]. Gastroenterology, 2004, 126(3): 693–702.
[21]Sun Q, Li W, She R, Wang D, Han D, Li R, Ding Y, Yue Z. Evidence for a role of mast cells in the mucosal injury induced by Newcastle disease virus[J]. Poult Sci, 2009, 88(3): 554–561.
[22]Francis H, Glaser S, DeMorrow S, Gaudio E, Ueno Y, Venter J, Dostal D, Onori P, Franchitto A, Marzioni M, Vaculin S, Vaculin B, Katki K, Stutes M, Savage J, Alpini G. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway[J]. Am J Physiol Cell Physiol, 2008, 295(2): C499-C513.
[23]Schneider E, M Rolli-Derkinderen, M Arock, Michel Dy. Trends in histamine research: New functions during immune responses and hematopoiesis[J]. Trends Immunol, 2002, 23(5): 255–262.
[24]Liu S, Xia Y, Hu H, Ren J, Gao C, Wood JD. Histamine H3 receptor-mediated suppression of inhibitory synaptic transmission in the submucous plexus of guinea-pig small intestine[J]. Eur J Pharmacol, 2000, 397(1): 49-54.
[25]Eutamene H, Theodorou V, Fioramonti J. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats[J]. Physiol, 2003, 553(pt.3): 959-966.
[26]Crowell MD, Jones MP, Harris LA, Dineen TN, Schettler VA, Olden KW. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes[J]. Curr Opin Investig Drugs, 2004, 5(7): 736-742.
[27]王承党,郑雪雁,郑玮玮.结肠黏膜低度炎症对大鼠内脏感觉的影响[J].世界华人消化杂志, 2009, 17(16): 1621-1625.
[28]王承党.重视黏膜炎症在肠易激综合征发病机制中的地位[J].胃肠病学, 2008 , 13(9): 513-515.
[29]Rijnierse A, Koster AS, Frans P N, Kraneveld AD. TNF-αis crucial for the development of mast cell-dependent colitis in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 291(5): G969-G976.
[30]Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors[J]. Gastroenterology, 2000, 119(4): 1148-1157.
[31] Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome[J]. Cut, 2001, 49(6): 743-745.
[32]Kim SH, Shin TY. Amomum xanthiodes inhibits mast cell- mediated allergic reactions through the inhibition of histamine release and inflammatory cytokine production[J]. Exp Biol Med, 2005, 230(9): 681–687.
[33]Msxwell PR, Rink E, Kumar D. Antibiotics increase functional abdominal symptoms[J]. Gastroenterology, 2002, 97(1): 104-108.
[34]Farthing MJG. Irritable bowel , irritable body , or irritable brain[J]? Br Med J, 1995, 310(6973): 171-175.
[35]Nicholl CG, Friedman G, Whitehead WE, Bloom SR. Effect of enprostil on gastric emptying , intestinal transit time and post-prandial release of gastrointestinal peptides[J]. Digestion, 1989, 43(1-2): 47-54.
[36]Gwee KA, Collins SM, Read NW. Increased rectal mucosal expression of interleukin 1βin recently acquired post-infectious irritable bowel syndrome[J]. Gut, 2003, 52(4): 523-526.
[37]Gonsalkorale WM, Perrey C, Pravica V, P J Whorwell, I V Hutchinson. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component[J]. Gut, 2003, 52(1): 91-93.